Preparedness for HPAI A(H5N1) Virus Varies Across Jurisdictions
By Elana Gotkine HealthDay Reporter
TUESDAY, May 21, 2024 -- Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses, according to a research letter published online May 21 in the Journal of the American Medical Association.
Noting that HPAI A(H5N1) clade 2.3.4.4b viruses pose pandemic potential, Noah Kojima, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined components of public health preparedness and response to HPAI A(H5N1) viruses. State and territorial epidemiologists in 55 jurisdictions were surveyed.
The researchers found that 91 percent of jurisdictions (50 jurisdictions) reported persons exposed to A(H5N1) virus-infected animals and monitored for symptoms. Of these, human exposures were reported in backyard flocks, commercial poultry, wild birds, and sick or dead mammals in 88, 82, 54, and 18 percent of jurisdictions, respectively. Overall, 59 percent of 49 jurisdictions with A(H5) virus testing capacity reported testing respiratory specimens from symptomatic persons since January 2022. Public health authorities reported difficulties in monitoring A(H5N1) virus-exposed persons due to personnel shortages or lack of funding in 66 percent of 50 jurisdictions. Overall, 19 of 50 respondents (38 percent) reported recommending empirical antiviral treatment before performing influenza testing for persons monitored after exposure to A(H5N1) virus who developed symptoms. One-third of the jurisdictions would recommend postexposure prophylaxis for close contacts of those with laboratory-confirmed A(H5N1).
"Challenges reported in monitoring exposed persons and differences in antiviral recommendations highlight the need to strengthen and standardize public health preparedness and response to HPAI A(H5N1) viruses in the U.S., particularly if additional animal-to-human A(H5N1) virus transmission events are reported," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
No Evidence That Live Vaccines Are Unsafe for Patients on Dupilumab
FRIDAY, June 14, 2024 -- There is no evidence to suggest that administration of live vaccines to patients receiving dupilumab is unsafe, and vaccine efficacy is not affected by...
Systemic Side Effects of COVID-19 Vaccine Tied to Greater nAB Response
TUESDAY, June 11, 2024 -- Short-term systemic side effects of the severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA vaccine are associated with greater long-lasting...
No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.